WO2002040023A1 - Nouvelle utilisation - Google Patents

Nouvelle utilisation Download PDF

Info

Publication number
WO2002040023A1
WO2002040023A1 PCT/US2001/043995 US0143995W WO0240023A1 WO 2002040023 A1 WO2002040023 A1 WO 2002040023A1 US 0143995 W US0143995 W US 0143995W WO 0240023 A1 WO0240023 A1 WO 0240023A1
Authority
WO
WIPO (PCT)
Prior art keywords
infection
group
virus
alkyl
human
Prior art date
Application number
PCT/US2001/043995
Other languages
English (en)
Inventor
Susan B. Dillon
Ruth Tal-Singer
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU2002219846A priority Critical patent/AU2002219846A1/en
Publication of WO2002040023A1 publication Critical patent/WO2002040023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

La présente invention concerne un procédé de traitement ou de prophylaxie du rhume ou de l'infection virale respiratoire provoquée par une infection due au rhinovirus humain (HRV), par d'autres entérovirus ou coronavirus, par le virus de la grippe, par le virus parainfluenza, par le virus respiratoire syncytial ou par une autre infection par adénovirus chez un homme nécessitant un traitement, ledit procédé consistant à administrer à cet homme une quantité efficace d'un antagoniste NK3.
PCT/US2001/043995 2000-11-16 2001-11-14 Nouvelle utilisation WO2002040023A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219846A AU2002219846A1 (en) 2000-11-16 2001-11-14 Novel use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24920400P 2000-11-16 2000-11-16
US60/249,204 2000-11-16

Publications (1)

Publication Number Publication Date
WO2002040023A1 true WO2002040023A1 (fr) 2002-05-23

Family

ID=22942465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/043995 WO2002040023A1 (fr) 2000-11-16 2001-11-14 Nouvelle utilisation

Country Status (2)

Country Link
AU (1) AU2002219846A1 (fr)
WO (1) WO2002040023A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582624B2 (en) 2002-09-20 2009-09-01 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
EP2217259A2 (fr) * 2007-10-19 2010-08-18 National Jewish Health Procédés de traitement de conditions avec déficience en composés contenant un groupe thiol
ES2860850A1 (es) * 2020-04-01 2021-10-05 Servicio Andaluz De Salud Agentes antivirales para el coronavirus
EP3939664A1 (fr) * 2020-07-17 2022-01-19 Consejo Superior De Investigaciones Científicas Composés destinés à être utilisés dans le traitement des infections virales par un virus de la famille des coronaviridae

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124316A (en) * 1994-03-18 2000-09-26 Sanofi Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124316A (en) * 1994-03-18 2000-09-26 Sanofi Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582624B2 (en) 2002-09-20 2009-09-01 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
US8119630B2 (en) 2002-09-20 2012-02-21 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
EP2217259A2 (fr) * 2007-10-19 2010-08-18 National Jewish Health Procédés de traitement de conditions avec déficience en composés contenant un groupe thiol
EP2217259A4 (fr) * 2007-10-19 2013-09-18 Nat Jewish Health Procédés de traitement de conditions avec déficience en composés contenant un groupe thiol
ES2860850A1 (es) * 2020-04-01 2021-10-05 Servicio Andaluz De Salud Agentes antivirales para el coronavirus
EP3939664A1 (fr) * 2020-07-17 2022-01-19 Consejo Superior De Investigaciones Científicas Composés destinés à être utilisés dans le traitement des infections virales par un virus de la famille des coronaviridae
WO2022013412A1 (fr) * 2020-07-17 2022-01-20 Consejo Superior De Investigaciones Científicas Composés destinés à être utilisés dans le traitement d'infections virales par un virus de la famille des coronaviridae

Also Published As

Publication number Publication date
AU2002219846A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
US11759467B2 (en) Treatment
EP2582433B1 (fr) Dérivés d'uréido-pyrazole destinés à être utilisés dans le traitement d'infections par un rhinovirus
CZ2002939A3 (cs) Léčivo pro léčení rýmy nebo virové infekce dýchacích cest a pneumonie indukované chřipkou
DK2968312T3 (en) drug combination
JP7304821B2 (ja) 細菌性二次感染の治療および／または予防における使用のためのｉｌ－８阻害剤
AU2010231955A1 (en) Pharmaceutical composition comprising a steroidal[3,2-c]pyrazole derivative and a second pharmaceutically active compound
WO2004067006A1 (fr) Combinaison d'un inhibiteur de la pde iv et d'un antagoniste du tnf-alpha
US20170281612A1 (en) Methods for the Treatment of Cystic Fibrosis
WO2002040023A1 (fr) Nouvelle utilisation
JP2007262082A (ja) 多発性硬化症の処置のためのリルゾールの使用
US20140024683A1 (en) Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
Gulati et al. Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators
JP2006508994A (ja) ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ
WO2000025766A2 (fr) Traitement de l'asthme gastrique
WO2022093871A1 (fr) Inactivation de sars-cov-2 par l'éthacridine
RU2774928C2 (ru) Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
JP2007500156A (ja) 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用
KR20130106267A (ko) 호흡기 이상 또는 질병의 치료를 위한 화합물
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
WO2021202745A1 (fr) Traitement du covid-19 à l'aide d'un composé sine
US20040097473A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
EP4333834A1 (fr) Utilisation d'un composé tel que le plérixafor pour le traitement d'une maladie pulmonaire virale
US20040092532A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
WO2002013825A1 (fr) Nouvelle utilisation pharmaceutique de dérivés quinnoliniques
JP2009511586A5 (ja) 気道分泌過多を処置するための組成物および方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP